Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 4Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Rectal Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 49Fluorouracil 45Leucovorin 42Capecitabine 40Irinotecan 31Bevacizumab 31Radiotherapy 24Cetuximab 23Radiation 13Panitumumab 13Folfox protocol 10Surgical Procedures, Operative 9IFL protocol 8Radiotherapy, Intensity-Modulated 6Magnetic Resonance Spectroscopy 6aflibercept 5Immunohistochemistry 5Gene Expression Profiling 5Chemotherapy, Adjuvant 5Fluorodeoxyglucose F18 4Floxuridine 4Celecoxib 4trifluridine tipiracil drug combination 3dehydroftorafur 3XELOX 3Sorafenib 3Ramucirumab 3Neoadjuvant Therapy 3Erlotinib Hydrochloride 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Rectal Neoplasms × CB-839 × Clear all
NCT02861300 2024-12-19

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Case Comprehensive Cancer Center

Phase 1/2 Completed
50 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡